COVID-19 vaccine

World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) ¹’² has also completed its review of the vaccine and recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks.
Vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined.

Once vaccinated with Sinopharm Covid-19 vaccine, the immune system can respond to an infection of live coronaviruses. B cells produce antibodies that stick to the invaders. Antibodies that target the spike protein can prevent the virus from entering cells¹.

Sinopharm’s clinical trials have demonstrated that Covid-19 vaccine can protect people against Covid-19. But no one can yet say how long that protection lasts. It’s possible that the level of antibodies drops over the course of months. But the immune system also contains special cells called memory B cells that might retain information about the coronavirus for years or even decades. As with all vaccinations under the EUL, Sinopharm will continue to submit ongoing data for the continued safety and quality of the vaccine.

According to the WHO ¹’², a large, multi-country phase three trial showed after administering two doses at an interval of 21 days, the Sinopharm Covid-19 vaccine is 79% effective against symptomatic SARS-CoV-2 infection two weeks after the second dose. It was also reported to be 79% effective against hospitalisation.

Sinopharm Covid-19 vaccine is not recommended for individuals with a history of anaphylaxis to any component of the Sinopharm Covid-19 vaccine or have body temperature over 38.5ºC should postpone vaccination until they no longer have a fever. Special population group of such as individuals with comorbidities, children and pregnant woman should check with their healthcare physician and refer to current country’s recommended vaccination criteria to determine if suitable for Sinopharm Covid-19 Vaccine.

According to WHO ¹’² recommendation, individuals should take two-dose with an interval of 3-4 weeks between first and second dose whilst the need for and timing of additional doses is still being assessed in clinical trials being conducted in various countries.

References:
1. The Sinopharm COVID-19 vaccine: What you need to know (2021, May 7). Retrieved July 27 2021 https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
2. Wilder-Smith, A., Hombach, J., Marti, M., & O’Brien, K. (2021, May 24). Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm. Retrieved July 27, 2021, from World Health Organisation website: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-2021.1
3. COVID-19 advice for the public: Getting vaccinated (2021, July). Retrieved July 28 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice

Disclaimer:

The information included and not limited to text, graphics, images and other material contained on this website are for educational purposes only and based on publicly available information and prepared to the best of Medic Surgical & Laser Clinic’s knowledge. No material on this site is intended to be substituted for professional medical advice. Always seek the advice of your physician or other qualified healthcare professional with any question relating to a medical condition or if you are eligible for vaccine as mentioned.

Medic Surgical & Laser Clinic is committed to safeguarding your privacy. We treat all personal data provided by you in strict confidence, and will only use your personal data in the manner of providing you updates of health-related news and updates of services including and not limited to Covid-19 Vaccine. All references to the “Medic Surgical & Laser Clinic”, “we”, “us” and “our” refer collectively to the Medic Surgical & Laser Clinic, and all its associates, and Clearbridge Medical Group, the parent holding company.